SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, Rosym
Search This Board:
Last Post: 3/3/2015 12:23:23 PM - Followers: 721 - Board type: Free - Posts Today: 12

Amarantus BioScience Holdings, Inc.

   Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
   The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
   The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
   The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
 For further information, please visit www.Amarantus.comor connect with the company in FacebookTwitter, LinkedIn & Google+


Large Pharmaceuticals and Biotech Startups Partnering To Develop Alzheimer’s Treatments
February 26, 2015
Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
"The LymPro® Assay: A Biomarker For Alzheimer's Disease Using Blood Samples From Clinically Diagnosed Alzheimer's Disease And Cognitively Intact Subjects," was accepted for poster presentation at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders  (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.
Feb. 23, 2015
Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) With Anavex Life Sciences Corp.
Feb. 18, 2015
Diagnostic and therapeutic products with potential for orphan drug designations in the areas of neurology, psychiatry, ophthalmology and regenerative medicine  -  17th Annual BIO CEO & Investor Conference
Feb. 10, 2015

New therapeutic principle for Parkinsonian dyskinesia shows clinical effect
Feb. 10, 2015
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia -  Eltoprazine is a small-molecule 5-HT1A/1B serotonin receptor agonist, investigational drug candidate, with a well-established safety profile. A Phase 2a dose-finding study was conducted with eltoprazine to determine its effect against levodopa-induced dyskinesia, in patients with Parkinson's disease (PD). The double-blind, randomized, placebo-controlled clinical study was led by Professor Per Svenningsson, M.D., Ph.D., Centre for Molecular Medicine, Karolinska Institutet, Professor Anders Björklund, Ph.D., Faculty of Medicine at Lund University, and Professor Håkan Widner, M.D., Ph.D., Faculty of Medicine at Lund University. The study was partially supported by a grant from Michael J. Fox Foundation for Parkinson's Research.
Feb. 10, 2015
New Test Claims It Can Tell If You Will Develop Alzheimer's... But Do You Want To Know?
Feb. 06, 2015
Amarantus to Present at the 17th Annual BIO CEO & Investor Conference on February 10, 2015
February 3, 2015
Amarantus Creates Alzheimer`s Disease Diagnostics Scientific Advisory Board

Congressman Fattah Meets with Biotech Company on Brain Research Efforts; Announced as Co-Chair of Alzheimer`s Caucus
February 03/15
Amarantus Diagnostics - First-Mover Advantage in the $3B Alzheimer’s Blood Test Market with a Business Strategy for Significant Near-Term Revenue in Multiple Sclerosis to Bridge the Gap
January 28th, 2015
Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board
Jan. 22, 2015
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015
Amarantus to Present at Noble Financial Capital Markets' Eleventh Annual Investor Conference
Jan. 13, 2015
Amarantus Announces Acquisition of Specialized Neuro-Diagnostics Company, DioGenix
Jan. 12, 2015

Developing an Accurate Test for Multiple Sclerosis

 Mar 5, 2014


December 12, 2014
SNNLive - Amarantus BioScience Holdings, Inc.


Oct. 19, 2014
Amarantus BioSciences



Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva

Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc

408-737-2734 x101

Gerald's email address

VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols

Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179 

  Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen  cool
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above and will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.

heart President & CEO, Gerald E. Commissiong - Noble Financial Capital Markets' Jan. 19, 2015 
Live audio webcast

heart Amarantus BioScience  Participate in the Bio CEO & Investor Conference 
Feb. 10, 2015 
 Hotel Venue The Waldorf Astoria New York

Live Audio Webcast  


"The LymPro® Assay: A Biomarker For Alzheimer's Disease Using Blood Samples From Clinically Diagnosed Alzheimer's Disease And Cognitively Intact Subjects," was accepted for poster presentation at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders  (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.    More information
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Current Report Filing (8-k) 02/26/2015 09:57:24 AM
AMBS News: Current Report Filing (8-k) 02/25/2015 04:53:11 PM
AMBS News: Current Report Filing (8-k) 02/13/2015 05:05:28 PM
AMBS News: Current Report Filing (8-k) 01/15/2015 04:17:14 PM
AMBS News: Current Report Filing (8-k) 01/15/2015 06:02:14 AM
#110746  Sticky Note Jason Napodano - 15 Biotech Names For 2015 Rosym 01/05/15 04:13:55 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#111872   Good to see that 786k bid creeping up, brharris 03/03/15 11:40:11 AM
#111871   this is the 3rd day with 1 MILLION Alapis 03/03/15 10:48:26 AM
#111870   Revenue is needed before this happens for sure. Titan V 03/03/15 10:35:29 AM
#111869   Question should be "are we loaded" JPetroInc 03/03/15 10:33:20 AM
#111868   are we locked? Alapis 03/03/15 10:06:04 AM
#111867   AMBS NEWS! Regenicin (RGIN) Receives $2.3 Million in TraderpennyX 03/03/15 09:46:36 AM
#111866   150,000,000 Share DILUTION Coming Sgt. Pepper 03/03/15 09:16:11 AM
#111865   TOXIC Financer DOMINION adds nearly 5% to ownership. Sgt. Pepper 03/03/15 09:15:59 AM
#111864   TOXIC FINANCER Dominion is the LARGEST shareholder Sgt. Pepper 03/03/15 09:15:46 AM
#111862   expensive and time consuming, but yes JPetroInc 03/03/15 06:41:41 AM
#111861   If AMBS were to IPO the diagnostic division, Titan V 03/02/15 10:13:33 PM
#111859   Progress Update - LymPro Partner JPetroInc 03/02/15 09:31:30 PM
#111857   3 Month Milestone Marker on LymPro Math JPetroInc 03/02/15 08:33:13 PM
#111856   8 Month Milestone Marker on LymPro Partnership JPetroInc 03/02/15 08:25:09 PM
#111855   WEEKLY TA CHART JPetroInc 03/02/15 08:14:25 PM
#111854   Good to see even the harshest and erroneous zoomboom 03/02/15 07:54:55 PM
#111853   50% of a $3 billion dollar market would zoomboom 03/02/15 07:52:53 PM
#111852   I tend to think that more than 70% joboggi 03/02/15 07:52:28 PM
#111851   That is always been the case. If you joboggi 03/02/15 07:46:03 PM
#111850   at the very least - Commish Jr. should JPetroInc 03/02/15 06:35:32 PM
#111849   Solid volume again today and another attempt to brharris 03/02/15 06:00:52 PM
#111848   Guess today's article wasn't the pps mover that JPetroInc 03/02/15 02:33:51 PM
#111846   micro and macro - not large Institutionals JPetroInc 03/02/15 11:20:26 AM
#111845   institutional investors can buy whatever they want...there are Alapis 03/02/15 11:12:55 AM
#111842   Institutionals can't buy pennies on the OTC - JPetroInc 03/02/15 10:51:06 AM
#111841   Revenue - that is the quintessential pps driver JPetroInc 03/02/15 10:49:50 AM
#111840   Chart is starting to shape up. Indicators starting brharris 03/02/15 10:18:06 AM
#111839   some institutional investor is starting to buy because Alapis 03/02/15 10:15:49 AM
#111838   great volume and action...the chart looks awsome Alapis 03/02/15 10:05:29 AM
#111837   they just tradd 800k at 8.5----more to come Alapis 03/02/15 10:01:36 AM
#111836   Where's that bid sitting at? No L2 oldmanhowie 03/02/15 09:59:43 AM
#111835   We've got lift off myersvodka 03/02/15 09:58:26 AM
#111834   1 million bid Alapis 03/02/15 09:52:54 AM
#111832   AMBS NEWS! Penny Stocks' Buzzers - New Energy TraderpennyX 03/02/15 09:40:20 AM
#111831   150,000,000 Share DILUTION Coming Sgt. Pepper 03/02/15 09:36:00 AM
#111830   TOXIC Financer DOMINION adds nearly 5% to ownership. Sgt. Pepper 03/02/15 09:35:46 AM
#111829   TOXIC FINANCER Dominion is the LARGEST shareholder Sgt. Pepper 03/02/15 09:35:33 AM
#111828   well spoken - and agreed JPetroInc 03/02/15 09:00:43 AM
#111827   Padin, I've held this security for more than JPetroInc 03/02/15 08:59:07 AM
#111826   Every time AMBS is mentioned in an article brharris 03/02/15 08:37:27 AM
#111825   I read over there as well. I agree brharris 03/02/15 08:28:02 AM
#111824   Articles are nice to read JPetroInc 03/02/15 08:02:50 AM
#111823   You are welcome its from the other AMBS zoomboom 03/02/15 07:53:35 AM
#111822   Nice DD zoom, thanks for posting. brharris 03/02/15 07:44:55 AM
#111820   Name one upcoming biotech company who has his sante1 03/01/15 10:55:26 PM
#111819   $AMBS mentioned. - Large Pharmaceuticals zoomboom 03/01/15 10:44:57 PM
#111818   Thank you so much.. Will be looking to Padin 03/01/15 09:38:26 PM
#111817   Plenty to cover for this year $22 million zoomboom 03/01/15 09:37:27 PM
#111816   Burn rate to revenue. Padin 03/01/15 09:34:42 PM
#111815   What part of the financials the $17 million zoomboom 03/01/15 09:30:27 PM